Overview

Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

Status:
Completed

Trial end date:
2006-12-01

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to estimate the number of patients with non-small cell lung cancer whose tumor responds to the treatments given in this study.

Phase:

Phase 2

Details

Lead Sponsor:

Eli Lilly and Company

Collaborator:

ImClone LLC

Treatments:

Cetuximab
Gemcitabine